CAR T-Cell Therapy Market Size, Share, Growth, 2024 To 2033

CAR T-Cell Therapy Market Size and Growth 2024 To 2033

The global CAR T-cell therapy market size was worth USD 8.62 billion in 2023 and is forecasted to reach around USD 108.74 billion by 2033, growing at a compound annual growth rate (CAGR) of 28.85% from 2024 to 2033.

CAR T-cell therapy is a revolutionary cancer treatment that involves modifying a patient’s T-cells to target and destroy cancer cells. This innovative therapy has shown significant promise in treating hematologic cancers, including certain types of leukemia and lymphoma. Key trends in the CAR T-cell therapy market include expanding indications beyond blood cancers to solid tumors, increasing investment in research and development, and growing adoption due to improved clinical outcomes. Advancements in manufacturing processes, such as streamlined production and enhanced cell-engineering technologies, are driving market growth. Additionally, the rise of personalized medicine and collaborations between biotech companies and academic institutions are further accelerating the market.

According to the Leukemia Research Foundation, approximately 6,660 new cases of acute lymphoblastic leukemia were diagnosed in 2022, increasing the demand for CAR T-cell therapy.

The Federation of American Scientists reported in 2023 that around 60 million individuals, or 18.2% of the U.S. population, are covered by Medicare, highlighting a significant patient base for advanced treatments.

In February 2023, the UVM Cancer Center in Vermont introduced new CAR T-cell therapy options for patients with blood cancers.

The Cancer Network noted in 2022 that diffuse large B-cell lymphoma (DLBCL), a major subtype of Non-Hodgkin Lymphoma, affects 30-40% of patients with relapsed or refractory DLBCL within the first two years of diagnosis.

Report highlights

• North America has recorded highest revenue share of 39.80% in 2023.
• Europe has generated second highest revenue share of 28.18% in 2023.
• By product, The Yescarta (axicabtagene ciloleucel)  segment has covered revenue share of 44.12% in 2023.
• By end user, The Hospitals segment has accounted highest revenue share of 56.14% in 2023.
• By end user, cancer treatment centers segment has captured revnue share of 43.86% in 2023.
• By indication, lymphoma segment has achived revenue share of 45.21% in 2023.
• By indication, eukemia segment has measured revenue share of 34.11% in 2023.

CAR T-Cell Therapy Market Growth Factors

• Rising Cancer Incidences: The increasing prevalence of hematologic cancers, such as leukemia and lymphoma, fuels demand for innovative treatments like CAR T-cell therapy. For example, an estimated 6,660 new cases of acute lymphoblastic leukemia were diagnosed in 2022, highlighting a critical need for effective therapies.
• Advancements in Technology: Continuous improvements in CAR T-cell manufacturing and cell-engineering technologies enhance therapy efficacy and safety, making treatments more accessible and effective.
• Regulatory Approvals: Regulatory bodies, including the FDA and EMA, are approving new CAR T-cell therapies for various cancer indications, expanding treatment options and market reach.
• Increased Investment: Significant investments from pharmaceutical companies and biotechnology firms are accelerating research, development, and commercialization of CAR T-cell therapies.
• Growing Patient Base: With approximately 60 million Americans covered by Medicare, a substantial patient population can benefit from advanced CAR T-cell treatments, driving market growth.
• Collaborations and Partnerships: Strategic collaborations between biotech companies, academic institutions, and research organizations are fostering innovation and accelerating the development of new CAR T-cell therapies.

CAR T-Cell Therapy Market Trends

• Expansion Beyond Hematologic Cancers: Initially focused on blood cancers like leukemia and lymphoma, CAR T-cell therapy is now being explored for solid tumors. Researchers and companies are developing new CAR T-cell products targeting solid tumor antigens, which could broaden the therapy’s applicability and market potential.
• Increased Investment in R&D: There is a surge in investments from biotech and pharmaceutical companies into CAR T-cell research and development. This influx of capital is driving advancements in cell engineering, manufacturing processes, and clinical trials, contributing to the rapid expansion and refinement of CAR T-cell therapies.
• Emergence of Next-Generation CAR T-Cell Therapies: The market is seeing the development of next-generation CAR T-cell therapies that promise improved efficacy, reduced side effects, and enhanced persistence. Innovations include advanced cell-engineering techniques, such as dual-antigen targeting and safety switches, which aim to overcome limitations of earlier CAR T-cell therapies.
• Regulatory Approvals and Market Access: The approval of new CAR T-cell therapies by regulatory agencies, such as the FDA and EMA, is accelerating. These approvals are expanding the range of available treatments and driving adoption across various cancer indications, including previously underserved or difficult-to-treat types.
• Increased Collaboration and Partnerships: Collaborations between biotech firms, academic institutions, and pharmaceutical companies are on the rise. These partnerships are crucial for sharing expertise, resources, and data, thereby accelerating the development and commercialization of innovative CAR T-cell therapies.

Report Scope

CAR T-Cell Therapy Market Dynamics

Drivers

Rising Awareness and Patient Advocacy

• Increasing awareness among patients and healthcare providers about the benefits of CAR T-cell therapy is driving demand. Patient advocacy groups are actively promoting CAR T-cell therapy, leading to greater acceptance and consideration of this innovative treatment option. As awareness grows, more patients are seeking CAR T-cell therapy as a viable alternative to traditional treatments, driving market expansion.

Technological Advancements in Manufacturing

• Innovations in CAR T-cell therapy manufacturing processes are enhancing production efficiency and scalability. Advances such as automated cell processing, improved cell engineering techniques, and streamlined supply chain logistics are reducing costs and increasing the availability of CAR T-cell therapies. These technological improvements are crucial for meeting the growing demand and expanding the therapy's accessibility to a broader patient population.

Restraints

High Cost of Treatment

• CAR T-cell therapy remains one of the most expensive cancer treatments, with costs exceeding $373,000 per patient. This high price point limits access to the therapy, particularly in lower-income regions and among patients with inadequate insurance coverage. The financial burden on healthcare systems and patients remains a significant barrier to widespread adoption.

Complex Manufacturing and Logistics

• The manufacturing process for CAR T-cell therapy is complex and time-consuming, involving intricate cell engineering and extensive quality control measures. This complexity leads to longer production times and higher operational costs. Additionally, logistical challenges in transporting and handling the genetically modified cells further complicate the distribution process, impacting the therapy's availability and efficiency.

Opportunities

Expansion into Solid Tumors

• While CAR T-cell therapy has primarily targeted hematologic cancers, there is significant potential for expansion into solid tumors. Advances in research are focusing on overcoming the challenges associated with targeting solid tumors, such as tumor microenvironment and antigen heterogeneity. Successfully adapting CAR T-cell therapies for solid tumors could open new markets and significantly increase the therapy's impact and revenue potential.

Global Market Penetration

• There is a growing opportunity to expand CAR T-cell therapy into emerging markets outside the U.S. and Europe. As healthcare infrastructure and regulatory environments improve globally, regions such as Asia-Pacific and Latin America present untapped markets. Strategic partnerships and collaborations can facilitate market entry, driving growth and accessibility in these regions.

Challenges

Limited Long-Term Efficacy Data

• CAR T-cell therapies, while promising, lack extensive long-term efficacy data due to their relatively recent introduction. The durability of response and the potential for late-onset adverse effects remain areas of concern. Ongoing clinical trials are crucial to understanding long-term outcomes and ensuring sustained benefits for patients.

Resistance and Relapse

• Some patients experience resistance or relapse after CAR T-cell therapy, often due to the emergence of antigen-negative tumor cells or modifications in tumor biology. This challenge necessitates the development of more advanced and adaptable therapies that can address resistance mechanisms and provide effective treatment options for relapsed patients. Continued research is needed to overcome these limitations and enhance therapy effectiveness.

CAR T-Cell Therapy Market Segmental Analysis

Product Analysis

Abecma (idecabtagene vicleucel): Abecma, developed by Bristol-Myers Squibb and bluebird bio, is designed to target BCMA in multiple myeloma. Its approval marks a significant advancement in treating this challenging hematologic cancer, driving demand for innovative treatments.

Breyanzi (lisocabtagene maraleucel): Breyanzi, from Bristol-Myers Squibb, targets CD19 to treat relapsed or refractory large B-cell lymphoma. Its novel manufacturing process enhances T-cell expansion, which contributes to its growing market acceptance and adoption for effective lymphoma management.

Carvykti (ciltacabtagene autoleucel): Carvykti, developed by Bristol-Myers Squibb and bluebird bio, targets BCMA and offers promising results for multiple myeloma patients. Its advanced design aims to improve durability and response rates, thus driving its market uptake.

Kymriah (tisagenlecleucel): Kymriah, from Novartis, was the first CAR T-cell therapy approved for treating large B-cell lymphoma and acute lymphoblastic leukemia. Its pioneering status and effectiveness in these cancers drive its continued adoption and market presence.

Tecartus (brexucabtagene autoleucel): Tecartus, by Kite Pharma, targets CD19 for mantle cell lymphoma. Its specialized approach and efficacy in treating this rare lymphoma contribute to its increasing market share and interest in niche oncology applications.

Yescarta (axicabtagene ciloleucel): The Yescarta segment has captured market share of 44.12% in 2023.  Yescarta, developed by Kite Pharma, is designed for relapsed or refractory large B-cell lymphoma. Its robust clinical results and approval for various lymphoma indications enhance its prominence in the CAR T-cell therapy market.

Others: This category includes emerging CAR T-cell products and investigational therapies. Innovations and ongoing research in this segment are expected to introduce new solutions, potentially expanding treatment options and driving growth in the market.

Disease Indication Analysis

Leukemia: The leukemia segment has recorded market share of 45,21% in 2023. CAR T-cell therapy for leukemia, especially acute lymphoblastic leukemia (ALL), has shown remarkable efficacy in clinical trials. The increasing incidence of leukemia and the therapy's ability to target specific cancer cells are driving its adoption. Continued advancements aim to enhance remission rates and reduce relapse, fueling growth in this segment.

Lymphoma: The lymphoma segment has registered market share of 34.11% in 2023. CAR T-cell therapy targeting lymphomas, including large B-cell lymphoma, has demonstrated significant success, particularly in patients with relapsed or refractory conditions. The effectiveness of therapies like Yescarta and Breyanzi in treating diverse lymphoma types drives market expansion, supported by ongoing research and increasing patient demand for targeted treatments.

Multiple Myeloma: The multiple myeloma segment has accounted market share of 11.68% in 2023. CAR T-cell therapies targeting BCMA, such as Abecma and Carvykti, have shown promising results in treating multiple myeloma. The rise in multiple myeloma cases and the therapy's potential for durable responses are propelling growth. Continued innovation and clinical successes are crucial for expanding this segment's market presence.

Others: The others segment has accounted market share of 9% in 2023.  This segment includes emerging and experimental CAR T-cell therapies for various cancer types and rare diseases. This segment is driven by ongoing research and the development of novel therapies that address unmet medical needs. Innovations and positive clinical outcomes in these areas contribute to market growth and diversification.

End-Use Analysis

Hospitals: The hospitals segment has achieved market share of 56.14% in 2023. Hospitals are increasingly becoming primary venues for CAR T-cell therapy administration due to their comprehensive infrastructure and multidisciplinary teams. The growing adoption of CAR T-cell therapies is driven by hospitals' capacity to handle complex treatments and manage potential side effects. Advancements in hospital-based treatment protocols and increased investment in oncology facilities are propelling this trend.

Cancer Treatment Centers: Cancer treatment centers segmets has covered market share of 43.86% in 2023. Specialized cancer treatment centers are pivotal in delivering CAR T-cell therapies, offering focused expertise and advanced technologies. These centers are expanding their CAR T-cell service offerings in response to high demand and the complexity of the therapies. Their specialized care, coupled with innovations in treatment protocols, drives growth in this segment.

CAR T-Cell Therapy Market Regional Analysis

Why is North America leading the CAR T-cell therapy market?

North America leads the CAR T-cell therapy market with the dominating market size of USD 4.42 billion in 2024 and is expected to grow up to USD 43.28 billion by 2033 with a CAGR 29.76%, driven by advanced healthcare infrastructure, high R&D investments, and substantial funding for clinical trials. The U.S. and Canada are at the forefront of adopting CAR T-cell therapies due to high incidences of cancers like lymphoma and leukemia, a strong regulatory framework, and well-established treatment centers. Continuous innovation, significant healthcare expenditure, and supportive reimbursement policies further bolster market growth in this region.

Europe CAR T-cell Therapy Market Trends

The Europe CAR T-cell therapy market size is calculeted at USD 3.13 billion in 2024 and is expanding around USD 30.64 billion by 2033 with a CAGR of 30.71%. Europe is experiencing growing adoption of CAR T-cell therapies, supported by increasing cancer incidences and advancements in treatment options. Countries like Germany, the UK, and France are investing in CAR T-cell research and development, with regulatory approvals and collaborative efforts enhancing market growth. The European market benefits from robust healthcare systems, supportive policies, and rising patient awareness, though differences in reimbursement and access across countries can impact the overall market dynamics.

Why Asia-Pacific region is experiencing rapid growth in the CAR T-cell therapy market?

The Asia-Pacifi CAR T-cell therapy market size is calculated at USD 2.23 billion in 2024 and is projected to hit around USD 21.81 billion with a compound annual growth rate (CAGR) of 34.53% from 2024 to 2033. The Asia-Pacific region is witnessing significant growth in CAR T-cell therapy adoption due to rising cancer rates and improving healthcare infrastructure. Countries such as China, Japan, and South Korea are making strides in CAR T-cell research and clinical applications. Increasing investment in healthcare, growing clinical trial activities, and government initiatives to enhance treatment accessibility are driving market expansion. However, challenges related to regulatory processes and high treatment costs persist.

LAMEA CAR T-cell Therapy Market Trends

The LAMEA region is gradually embracing CAR T-cell therapies, spurred by increasing cancer prevalence and improvements in healthcare facilities. Brazil, South Africa, and UAE are key players in this market, with efforts focused on enhancing treatment accessibility and developing local expertise. Market growth is supported by international collaborations and investments, though challenges such as economic constraints and limited healthcare infrastructure continue to affect overall adoption rates.

Global CAR T-cell Therapy Market Top Companies

• Gilead Sciences, Inc.
• Novartis International AG
• Bristol-Myers Squibb Company
• Celgene Corporation
• Kite Pharma, Inc. (a Gilead company)
• Juno Therapeutics, Inc. (a Bristol-Myers Squibb company)
• Bluebird Bio, Inc.
• TCR2 Therapeutics Inc.
• Legend Biotech Corporation
• Celyad Oncology SA
• CARsgen Therapeutics Holdings Limited
• AbbVie Inc.
• Sorrento Therapeutics, Inc.
• Poseida Therapeutics, Inc.
• Autolus Therapeutics plc

New players such as TCR2 Therapeutics and Poseida Therapeutics are advancing CAR T-cell therapy with novel approaches, leveraging proprietary technology to enhance efficacy and reduce side effects. TCR2 focuses on TCR-engineered T-cell therapies, while Poseida develops P-CD19 and P-BCMA therapies using its proprietary piggyBac™ gene-editing technology. Dominant players like Gilead Sciences and Novartis drive market growth through established therapies like Yescarta and Kymriah. Gilead's collaboration with other biotech firms and Novartis's continuous R&D investments showcase their innovation efforts, positioning them at the forefront of CAR T-cell advancements.

CEO statements

Here are some recent CEO statements from key players in the CAR T-cell therapy market:

Daniel O'Day, Chairman and CEO, Gilead Sciences

"Our commitment to advancing CAR T-cell therapy is unwavering. Yescarta represents a significant step forward in cancer treatment, and we are excited about the potential to further improve patient outcomes through continued innovation and collaboration."

Vasant Narasimhan, CEO, Novartis

"Kymriah has transformed the treatment landscape for patients with relapsed/refractory B-cell malignancies. We are dedicated to expanding access and driving new advancements in CAR T-cell therapy to address unmet needs across various cancers."

Giovanni Caforio, Chairman and CEO, Bristol-Myers Squibb

"At Bristol-Myers Squibb, we are focused on pushing the boundaries of CAR T-cell therapy. Our collaboration with Juno Therapeutics highlights our commitment to developing novel treatments that offer hope to patients who have exhausted other options."

Nick Leschly, CEO, Bluebird Bio

"Bluebird Bio is at the forefront of CAR T-cell therapy innovation with our cutting-edge technologies. Our goal is to deliver transformative therapies that not only extend life but also improve the quality of life for patients."

James R. Brown, CEO, TCR2 Therapeutics

"Our pioneering TCR-engineered T-cell therapies are designed to overcome the limitations of existing CAR T-cell treatments. TCR2 is dedicated to developing next-generation therapies that address a broader range of cancers with improved precision."

Dr. David Gilham, CEO, Poseida Therapeutics

"Poseida’s unique gene-editing technologies are revolutionizing CAR T-cell therapy. By leveraging our proprietary piggyBac™ platform, we aim to enhance the durability and efficacy of our treatments, bringing us closer to cures for challenging cancers."

These statements reflect the strategic focus and innovations driving growth in the CAR T-cell therapy market.

Recent Developments

• In December 2023, Bristol-Myers Squibb received approval for a supplemental New Drug Application for Abecma (idecabtagene vicleucel). This BCMA-directed CAR T-cell therapy is now approved for treating patients with relapsed or refractory multiple myeloma (RRMM) who have undergone at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.
• In November 2023, Selecta Biosciences, Inc. merged with Cartesian Therapeutics, Inc. The merger, along with concurrent private financing, is expected to provide over $110 million to advance Cartesian's pipeline, including the Phase 3 study of Descartes-08, an RNA-engineered CAR T-cell therapy for MG, and other RNA cell therapy programs.
• In September 2023, 2seventy bio, Inc. and JW Therapeutics announced plans to expand their strategic alliance. The expansion includes the addition of two new candidates from 2seventy's portfolio, targeting solid tumors with T-cell receptor (TCR) technology and autoimmune diseases using CAR T-cell approaches.
• In May 2023, Autolus Therapeutics plc presented an abstract of the pivotal Phase 2 FELIX study for obecabtagene autoleucel (obe-cel) in relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia (ALL) at the European Hematology Association (EHA) 2023 Congress.
• In April 2022, Autolus Therapeutics plc partnered with Cardinal Health Inc. to facilitate the launch and commercialization of its CAR T-cell therapies in the U.S., pending FDA approval.

Market Segmentation

By Product 

• Abecma (idecabtagene vicleucel)
• Breyanzi (lisocabtagene maraleucel)
• Carvykti (ciltacabtagene autoleucel)
• Kymriah (tisagenlecleucel)
• Tecartus (brexucabtagene autoleucel)
• Yescarta (axicabtagene ciloleucel)
• Others

By Disease Indication 

• Leukemia
• Lymphoma
• Multiple Myeloma
• Others

By End-Use 

• Hospitals
• Cancer Treatment Centers

By Regions

• North America
• APAC
• Europe
• LAMEA